For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Immune Modulator

Bronchogen

Also known as: AEDL, Ala-Glu-Asp-Leu, T-33, lung peptide bioregulator

Research use only · not FDA-approved

Synthetic short-chain tetrapeptide bioregulator (Ala-Glu-Asp-Leu, AEDL) from the Khavinson family of tissue-specific peptides, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology and designed from amino-acid analysis of bronchial-mucosa peptide extracts. It is proposed to act epigenetically, penetrating cells and binding DNA to modulate tissue-specific gene expression and protein synthesis in bronchial epithelium and lung tissue. Evidence is almost entirely preclinical and from Russian-language sources; no controlled human clinical trials meeting international standards have been published. It is not FDA-approved or FDA-evaluated and is sold as a grey-market research compound.

Where to buy · live market data

Who's worth your money for Bronchogen

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (96) of 3 scored sellers

$3.50/mg

$69.97 · 20mg · 99.6% purity

5 COAs
Buy code MERIT · 15% off

Best value

Lowest $/mg among scored sellers

$3.95/mg

$79.00 · 20mg · 99.6% purity

Average price

$3.84/mg

Sellers

8

45-day trend

+11.8%

7 of 8 sellers have a current price· 1 stale hidden· 3 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Bronchogen

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Bronchogen

CAS

Molecular formula

C18H30N4O9

Sequence

AEDL

Typical dose range

No validated human dose; vendor 'research' protocols commonly cite ~2-3 mg/day for 10-20 day courses (subcutaneous, unverified, research-only)

Half-life

Short circulating half-life (minutes); like other Khavinson bioregulators, biological effects are claimed to outlast plasma presence. Not formally characterized in humans.

Common research uses

respiratory/bronchial tissue research (research only)investigational respiratory-aging and lung-function studies (preclinical)

Safety notes

Not FDA-approved or evaluated; no rigorous human safety data exist. Sold for research use only; human use is off-label and unvalidated. Not currently a WADA-listed substance.

Reconstitution

Sold as lyophilized powder; reconstitute with bacteriostatic water and refrigerate. Research-use only.

Research depth

13 citations indexed for Bronchogen

All research on Bronchogen →

review · 2021

Peptide Regulation of Gene Expression: A Systematic Review

Peptides are characterized by their wide range of biological activity: they regulate functions of the endocrine, nervous, and immune systems.

review · 2020

Peptides: Prospects for Use in the Treatment of COVID-19

There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons.

Study · 2020

AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism

It was shown that AEDG peptide (Ala-Glu-Asp-Gly, Epitalon) regulates the function of the pineal gland, the retina, and the brain. AEDG peptide increases longevity in animals and decreases experimental cancerogenesis.

Study · 2017

Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum

Exogenous short biologically active peptides epitalon (Ala-Glu-Asp-Gly), bronchogen (Ala-Glu-Asp-Leu), and vilon (Lys-Glu) at concentrations 10 -7 -10 -9 M significantly influence growth, development, and differentiation of tobacco (Nicotiana tabacum) callus cultures.

animal · 2017

[ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]

The effect of the tetrapeptide bronchogen on the structural and functional state of the bronchial epithelium and inflammatory activity in the lungs was studied in the chronic obstructive pulmonary disease (COPD) model, created in rats by a 60-day intermittent exposure to nitrogen dioxide.

animal · 2015

Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology

On the model of chronic obstructive pulmonary disease, the effect of therapy with low-molecular-weight peptides on restructuring and functional activity of bronchial epithelium for restoring the immune and barrier function of the lungs and prevention of inflammatory process progression was studied.

Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.